Ocriplasmin

What is Ocriplasmin?

Ocriplasmin is a synthetic, truncated form of human plasmin, a naturally occurring enzyme. As a proteolytic enzyme, it's specifically developed for ophthalmic use, administered as an intravitreal injection directly into the eye. Its primary function is to dissolve protein components causing abnormal traction between the vitreous humor and the macula, a condition known as vitreomacular adhesion (VMA). This medication offers a non-surgical ophthalmological treatment option for specific retinal disorders, providing an alternative to more invasive procedures for suitable patients. It is marketed under brand names such as Jetrea.

How Does it Work?

The mechanism of action of Ocriplasmin involves its powerful proteolytic activity. Injected into the vitreous humor, it acts as a proteolytic enzyme by targeting key proteins like fibronectin, laminin, and collagen at the vitreoretinal interface. In vitreomacular adhesion (VMA), these proteins create an abnormally strong attachment, causing traction on the macula. By selectively cleaving these proteins, Ocriplasmin weakens and releases this adhesion, facilitating vitreous separation from the macula. This enzymatic action relieves traction, aiming to restore normal macular anatomy and improve visual outcomes.

Medical Uses

The primary medical use for Ocriplasmin is treating symptomatic vitreomacular adhesion (VMA). Symptomatic VMA occurs when the vitreous gel pulls abnormally on the macula, leading to blurred vision, distorted vision (metamorphopsia), and reduced visual acuity. In some cases, it can progress to a macular hole, a full-thickness defect in the macula. Ocriplasmin is indicated for adult patients with symptomatic VMA, including those with a macular hole of 400 microns or less. Clinical studies demonstrate its efficacy in achieving vitreomacular separation and, for some, closing macular holes, potentially reducing the need for surgical intervention (vitrectomy). Treatment decisions are based on thorough ophthalmic examination, including optical coherence tomography (OCT) imaging.

Dosage

The standard dosage for Ocriplasmin is a single intravitreal injection of 0.125 mg into the affected eye. This is typically a one-time treatment performed by a qualified ophthalmologist under aseptic conditions. Before the procedure, topical anesthesia and povidone-iodine for sterilization are used. Patients are monitored post-injection for immediate adverse reactions and must follow post-injection instructions, including avoiding rubbing the eye and promptly reporting any new or worsening symptoms. Treatment effectiveness is assessed over several weeks through follow-up appointments to monitor vitreomacular separation and visual acuity. Repeat injections are not currently recommended.

Side Effects

While generally well-tolerated, Ocriplasmin can cause side effects, mostly related to the intravitreal injection or the drug's activity.

• Visual disturbances (blurred vision, floaters, flashes of light)
• Eye pain/discomfort, conjunctival hemorrhage
• Vitreous opacities, retinal edema, increased intraocular pressure
• Chromatopsia (seeing colored fringes)

Less common but serious side effects can include:

• Retinal detachment, endophthalmitis (severe eye infection)
• Lens subluxation, macular hole progression or new formation
• Permanent vision loss

Patients should contact their ophthalmologist immediately for severe eye pain, sudden vision loss, increased light sensitivity, or signs of infection. Regular follow-up is crucial.

Drug Interactions

No specific drug-drug interaction studies have been conducted with Ocriplasmin. Given its localized intravitreal injection and enzymatic action within the eye, systemic drug interactions are unlikely. However, patients must inform their ophthalmologist about all medications, including prescription, over-the-counter, herbal supplements, and vitamins. This ensures assessment of overall health and potential contraindications. Concomitant use of other ophthalmic medications, particularly those affecting intraocular pressure or inflammation, requires careful management. It's generally advised to avoid concurrent use of other intravitreal medications in the same eye unless specifically directed by an ophthalmologist.

FAQ

Q: What is Ocriplasmin used for?

A: Ocriplasmin treats symptomatic vitreomacular adhesion (VMA), including cases with a small macular hole, by releasing abnormal traction on the macula.

Q: How is Ocriplasmin administered?

A: It's given as a single intravitreal injection into the affected eye by an ophthalmologist.

Q: Can Ocriplasmin cure macular holes?

A: It can help close macular holes up to 400 microns by relieving traction, but success varies and it's not a guaranteed cure for all macular holes.

Q: How quickly does Ocriplasmin work?

A: Vitreomacular separation typically occurs within 28 days, with visual improvements often reported over several weeks post-injection.

Q: What are alternatives to Ocriplasmin?

A: Options include observation for mild cases or pars plana vitrectomy surgery, a more invasive procedure.

Products containing Ocriplasmin are available through trusted online pharmacies. You can browse Ocriplasmin-based medications at ShipperVIP or Medicenter.

Summary

Ocriplasmin is a valuable ophthalmological treatment for symptomatic vitreomacular adhesion (VMA), including those with a small macular hole. As a proteolytic enzyme, it dissolves key proteins at the vitreoretinal interface, releasing abnormal traction on the macula. Administered as a single intravitreal injection, it offers a non-surgical alternative for selected patients, aiming to improve visual acuity and potentially avoid more invasive procedures. While generally safe, patients should be aware of potential ocular side effects and maintain close follow-up with their ophthalmologist. Its targeted enzymatic action represents a significant advancement in managing specific retinal conditions.